Back to search results

Phase 1 Study of BA3182 for Advanced Adenocarcinoma

This study is testing a new treatment called BA3182 for people with advanced adenocarcinoma (a type of cancer that starts in glandular cells). BA3182 is a special type of antibody designed to target cancer cells. The main goals of this study are to see how safe BA3182 is, find the highest dose that can be given safely, and see if it shrinks tumors. You might be able to join if you have advanced adenocarcinoma that cannot be removed by surgery or has spread, are at least 18 years old, and have good organ function. The study is currently recruiting about 168 participants.

Study design
This is an open-label, Phase 1 study, meaning both you and your doctors will know you are receiving BA3182. It aims to enroll 168 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study will track your progress for up to 24 months to assess safety and how well the treatment works.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05808634

Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.

Recruiting
PHASE1Ages 18+InterventionalTreatment
BioAtla, Inc.
~168 participants
Updated 2025-09-25 on ClinicalTrials.gov
What's tested:BA3182

At a glance

Recruiting sites
9 of 9 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Part 1: Assess dose limiting toxicity as defined in the protocol
Measured over Up to 24 months
+2 more outcomes measured

Conditions

Advanced Adenocarcinoma

Explore related trials

Adenocarcinoma

Where it's being run

9 sites across 6 states
California2
Illinois2
Ohio2
Connecticut1
Michigan1
Washington1

Who to contact

BioAtla Medical Affairs
[email protected]
858-558-0708 · ext. 3333
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Histologically or cytologically confirmed locally advanced unresectable or metastatic adenocarcinoma
Age ≥ 18 years
Adequate renal function
Adequate liver function
Adequate hematological function
Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

Exclusion

Patients must not have clinically significant cardiac disease.
Patients must not have known non-controlled CNS metastasis.
Patients must not have active autoimmune disease or a documented history of autoimmune disease.
Patients must not have a history of ≥ Grade 3 allergic reactions to mAb therapy as wellas known or suspected allergy or intolerance to any agent given during this study.
Patients must not incomplete recovery from the effects of major surgery or significant traumatic injury before the first dose of study treatment.
Patients must not have known human immunodeficiency virus (HIV) infection, active hepatitis B and/or hepatitis C.
Patients must not be women who are pregnant or breast feeding.

What this trial measures

  • Part 1: Assess dose limiting toxicity as defined in the protocolUp to 24 months

    Phase 1 Part 1: Safety Profile of BA3182

  • Part 1: Assess maximum tolerated dose as defined in the protocolUp to 24 months

    Phase 1 Part 1: Safety Profile of BA3182

  • Part 2: Confirmed overall response rate (ORR) per RECIST v1.1Up to 24 months

    Phase 1 Part 2: Antitumor activity of BA3182